MedTrace Logo

A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies

NCT05955105 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2024-05-21

No results posted yet for this study

Summary

This is a multicenter, open-label, phase Ib/IIa study. The first part of the study will evaluate the safety, tolerability and preliminary efficacy of ILB2109 and Toripalimab in patients with locally advanced or metastatic solid malignancies. The second part of the study will evaluate the efficacy of ILB2109 and Toripalimab in patients with selected advanced solid malignancies.

Conditions

Interventions

DRUG

ILB-2109

ILB-2109 tablets will be administered by mouth every day in 21-day cycles

DRUG

Toripalimab

Toripalimab injection will be administered via IV every 21 days.

Sponsors & Collaborators

  • Innolake Biopharm

    lead INDUSTRY

Principal Investigators

  • Jin Li, M.D. · Shanghai East Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-25
Primary Completion
2026-01-25
Completion
2026-07-24

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05955105 on ClinicalTrials.gov